Protara Therapeutics (TARA) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $28.00 from $25.00 | May 20, 2026 |
| JP Morgan | Maintained | Overweight | $26.00 from $27.00 | May 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $27.00 from $23.00 | Apr 29, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $27.00 | Mar 4, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Feb 10, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $24.00 | Jan 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Dec 3, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Nov 19, 2025 |
| Jones Trading | Initiated Coverage | Buy | $21.00 | May 22, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Apr 28, 2025 |
| Scotiabank | Initiated Coverage | Sector Outperform | $12.00 | Apr 16, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Mar 14, 2025 |
| LifeSci Capital | Initiated Coverage | Outperform | $22.00 | Mar 11, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Mar 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Dec 6, 2024 |
| Guggenheim | Maintained | Buy | $20.00 | Dec 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Nov 14, 2024 |
| Oppenheimer | Maintained | Outperform | $25.00 from $30.00 | Aug 12, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | Aug 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 | May 6, 2024 |
Frequently asked questions
Is TARA a buy, sell, or hold?
Analysts covering Protara Therapeutics currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on TARA?
On May 20, 2026, Oppenheimer maintained Protara Therapeutics at Outperform with a price target of $28.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.